Literature DB >> 16101185

Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas.

Emilios E Pakos1, Ann C Goussia, Pericles G Tsekeris, Dionysios J Papachristou, Dimitrios Stefanou, Niki J Agnantis.   

Abstract

The aim of the present study was to evaluate the association of vascular endothelial growth factor (VEGF) and its receptor, KDR/Flk-1, with tumor grade, microvessel density (MVD) and clinical outcome in patients with soft tissue sarcomas (STSs). Tissue specimens of 28 patients with STSs were analyzed immunohistochemically using specific monoclonal antibodies. Tissue samples were obtained prior to any treatment. Half of the STSs exhibited strong expression of VEGF that was associated statistically significantly with high tumor grade. Strong expression of KDR/Flk-1 was detected in only 2 sarcomas. No association was demonstrated between VEGF and KDR/Flk-1 expression. MVD was significantly associated with tumor grade and was higher in sarcomas with strong VEGF expression. Limited data on clinical outcome precluded solid analyses for an association with disease progression. This study provides further evidence on the role of VEGF and MVD in tumor aggressiveness in STSs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101185

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

Review 1.  Systemic management strategies for metastatic soft tissue sarcoma.

Authors:  Sujana Movva; Claire Verschraegen
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

2.  A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

Authors:  H J Mackay; R J Buckanovich; H Hirte; R Correa; P Hoskins; J Biagi; L P Martin; G F Fleming; R Morgan; L Wang; R Polintan; A M Oza
Journal:  Gynecol Oncol       Date:  2011-12-02       Impact factor: 5.482

Review 3.  Targeted therapy in sarcomas other than GIST tumors.

Authors:  Douglas Sborov; James L Chen
Journal:  J Surg Oncol       Date:  2014-10-20       Impact factor: 3.454

4.  Analysis of HIF-1a and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications.

Authors:  Jui-Han Huang; Frank S Lee; Theresa L Pasha; Mary D Sammel; Giorgos Karakousis; George Xu; Douglas Fraker; Paul J Zhang
Journal:  Cancer Biol Ther       Date:  2009-12-22       Impact factor: 4.742

5.  A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.

Authors:  M Agulnik; R L B Costa; M Milhem; A W Rademaker; B C Prunder; D Daniels; B T Rhodes; C Humphreys; S Abbinanti; L Nye; R Cehic; A Polish; C Vintilescu; T McFarland; K Skubitz; S Robinson; S Okuno; B A Van Tine
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

6.  Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

Authors:  S Tariq Mahmood; Samuel Agresta; Carlos E Vigil; Xiuhua Zhao; Gang Han; Gina D'Amato; Ciara E Calitri; Michelle Dean; Christopher Garrett; Michael J Schell; Scott Antonia; Alberto Chiappori
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

Review 7.  Emerging therapeutic targets for soft tissue sarcoma.

Authors:  Jason L Smith; Richard F Riedel
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

8.  Differential expression of angiogenic factors in peripheral nerve sheath tumors.

Authors:  Junji Wasa; Yoshihiro Nishida; Yoshitaka Suzuki; Satoshi Tsukushi; Yoji Shido; Kozo Hosono; Yoshie Shimoyama; Shigeo Nakamura; Naoki Ishiguro
Journal:  Clin Exp Metastasis       Date:  2008-08-05       Impact factor: 5.150

9.  Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.

Authors:  Thomas Brodowicz; Bernadette Liegl-Atzwager; Emmanuelle Tresch; Sophie Taieb; Andrew Kramar; Viktor Gruenwald; Marie Vanseymortier; Stéphanie Clisant; Jean-Yves Blay; Axel Le Cesne; Nicolas Penel
Journal:  BMC Cancer       Date:  2015-03-14       Impact factor: 4.430

Review 10.  Pazopanib: approval for soft-tissue sarcoma.

Authors:  Diana T Nguyen; Sepideh Shayahi
Journal:  J Adv Pract Oncol       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.